News
BGNE
168.11
+6.00%
9.52
BeiGene Hold Rating Justified by Mixed Sales Performance and Competitive Market Pressures
TipRanks · 11h ago
Tracking Baker Brothers Portfolio - Q1 2024 Update
Seeking Alpha · 1d ago
Weekly Report: what happened at BGNE last week (0603-0607)?
Weekly Report · 2d ago
Beigene Ltd: Statement of changes in beneficial ownership of securities
Press release · 4d ago
Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Immunocore Holdings (IMCR) and COMPASS Pathways (CMPS)
TipRanks · 06/03 11:40
Weekly Report: what happened at BGNE last week (0527-0531)?
Weekly Report · 06/03 09:05
We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation
BeiGene, Ltd. (NASDAQ:BGNE) will host its Annual General Meeting on 5th of June. Over the past three years, the total loss to shareholders has been 58% in BeiGene's share price. CEO pay for John Oyler is comparable to the industry average. BeiGene has seen its earnings per share grow by 13% a year over the last three years. The company pays a smaller salary for its CEO than other companies in the same industry. The AGM could be an opportunity for shareholders to voice their concerns.
Simply Wall St · 05/30 11:39
BriaCell signs supply agreement with Beigene for metastatic breast cancer treatment
Healthcare BriaCell signs supply agreement with Beigene for metastatic breast cancer treatment. Phase 1/2 clinical trial will evaluate the safety and efficacy of Bria-OTS in combination with BeiGene's anti-PD-1 antibody for the treatment of advanced breast cancer.
Seeking Alpha · 05/28 12:45
Weekly Report: what happened at BGNE last week (0520-0524)?
Weekly Report · 05/27 09:05
Lululemon Athletica Was Among The Worst-Performing Stocks Last Week (May 19-May 26, 2024): Are These 10 Large-Cap Stock Losers In Your Portfolio?
National Grid Transco decreased after the company reported an equity raise of £7 billion. KE Holdings Inc lost 14% in the last week. XP Inc. Reported worse-than-expected Q1 financial results. Walgreens Boots Alliance, Inc. And Lululemon Athletica were among the worst performers.
Benzinga · 05/26 15:16
Week In Review: Hengrui And Dearon Announce $7.2B In Drug Licensings
Seeking Alpha · 05/26 06:45
BeiGene Says BRUKINSA Data At American Society Of Clinical Oncology (ASCO) Annual Meeting In Chicago Underscore Differentiated Clinical Profile For Treatment Of CLL And SLL
The presentations highlight analyses of the efficacy and safety of BRUKINSA compared to other BTKis used to treat chronic lymphocytic leukemia and small lymphocytics lymphoma. The new analyses highlight improved PFS and response rates and a low usage of antihypertensive medicines.
Benzinga · 05/24 10:05
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
New analyses for BRUKINSA will be presented at the American Society of Clinical Oncology Annual Meeting in Chicago, May 31 - June 4, 2024. The presentations highlight analyses of the efficacy and safety of BRUKinSA compared to other BTKis used to treat chronic lymphocytic leukemia. The analysis found a statistically significant improvement in PFS and a low usage of antihypertensive medicines.
Barchart · 05/24 05:00
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
NASDAQ · 05/20 17:13
Weekly Report: what happened at BGNE last week (0513-0517)?
Weekly Report · 05/20 09:04
BeiGene (BGNE) Shares Cross Above 200 DMA
NASDAQ · 05/17 20:32
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Sanara MedTech (SMTI)
TipRanks · 05/15 11:20
BeiGene Performance Analysis: A Hold Rating with Cautious Optimism Amidst Competitive Pressures
TipRanks · 05/15 09:40
BeiGene To Highlight New Hematology Portfolio And Pipeline Data At EHA2024, June 13-16, 2024
Benzinga · 05/14 20:16
More
Webull provides a variety of real-time BGNE stock news. You can receive the latest news about Beigene Ltd through multiple platforms. This information may help you make smarter investment decisions.
About BGNE
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.